Mettler Toledo management check

MTD · Health Care · Life Sciences Tools & Services · CEO Patrick Kaltenbach

Filings as of

76
Management score, ranked 108th of 487 · 10th of 60 in Health Care5 good · 2 to watch · 0 flaggedStrongest: clean books · Weakest: stable leadership · Best and worst run in Health Care →

The seven checks

  • Good

    Have owners done well?

    Beat its chosen peersOwners$122Peers$106

    What $100 became since fiscal 2021

    7068th
    Detail

    $100 invested at the start of fiscal 2021 grew to $122, against $106 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns20212025

    Pay actually paid $100 value, each on its own scale

    9273rd
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.84 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Good

    What does the CEO cost owners?

    0.8% of net income

    $6.7m pay · $869.2m net income, FY2025

    0.1%1%3%10%
    5960th
    Detail

    $6.7m of reported pay in fiscal 2025, against $869.2m of net income.

  • Watch

    Do they own the stock?

    Insiders are selling

    5,510 shares

    6 mo: ▲ $0 bought · ▼ $6.8m sold

    ——
    Detail

    4 insiders sold $6.8m in the last six months and none bought.

  • Good

    Are owners being diluted?

    Share count shrinking2021 · 23m2025 · 21m

    Diluted shares −3.0% a year; flagged above +2%

    0%10%20%

    Stock pay 0.6% of revenue

    8879th
    Detail

    Diluted shares changed -3.0% a year over the last three fiscal years. Stock-based pay was 0.6% of revenue in the latest year.

  • Watch

    Is leadership stable?

    2 CEOs in the pay table

    8 filings under 8-K 5.02 in 3 years

    0101420+

    CEOs: Olivier Filliol, Patrick Kaltenbach

    4521st
    Detail

    CEOs in the pay table: Olivier Filliol, Patrick Kaltenbach. 8 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 010-K amended
    100100th
    Detail

    No restatements, auditor changes or late filings since 2021.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed March 18, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
$0$8.6m$17.2m$10020212022202320242025$122$106

Other key measuresNon-GAAP earnings per shareNet cash flowGroup sales at budgeted currency ratesTotal shareholder return relative to the S&P 500 Healthcare Index and the S&P 500 Industrials Index

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Patrick Kaltenbach$6.7m$8.8m$1.9m$122$106$869.2m
2024Patrick Kaltenbach$6.9m$6.5m$1.6m$107$102$863.1m
2023Patrick Kaltenbach$8.5m$4.7m$1.4m$106$103$788.8m
2022Patrick Kaltenbach$6.5m$4.6m$1.5m$127$109$872.5m
2021Olivier Filliol, Patrick Kaltenbach$12.0m$17.2m$2.0m$149$139$769.0m

Insiders and the CEO's stakeSelling

President and CEO
Patrick Kaltenbach
Shares held
5,510
Latest Form 4
Nov 12, 2026

4 insiders sold $6.8m in the last six months and none bought.

Open-market trades by officers and directors since May 21, 2026.

  • SoldShawn VadalaChief Financial Officer$3.2mAug 3, 2026
  • SoldPatrick KaltenbachPresident and CEO$1.3mAug 27, 2026
  • SoldThomas P SaliceDirector$1.2mAug 5, 2026
  • SoldGerry KellerHead of Process Analytics$1.1mNov 9, 2026

Leadership and governance on file

20222023202420252026Leadership 14Votes 6
All 14 filings

Latest shareholder vote results: May 11, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $4.6bn returned to owners in buybacks and dividends, 112% of net income, and $99.7m of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$550.0m$1.1bn20212022202320242025Shares23m23m22m21m21m
Show the figures
Fiscal year20212022202320242025
Revenue$3.7bn$3.9bn$3.8bn$3.9bn$4.0bn
Net income$769.0m$872.5m$788.8m$863.1m$869.2m
Stock-based pay$19.6m$19.7m$17.9m$20.0m$22.5m
Buybacks$1000.0m$1.1bn$900.0m$850.0m$800.0m
Dividends—————
Diluted shares23m23m22m21m21m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.